Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paresh Vyas

Showing results (11-20 of 201) with videos related to

Pageof 21
Sort By:
Early Human Development|October 27, 2006
Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesisParesh Vyas, Irene Roberts
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AMLGert Ossenkoppele, Paresh Vyas
Clinical Medicine (London, England)|April 28, 2018
From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemiaNiels Asger Jakobsen, Paresh Vyas
Blood|October 9, 2008
Good news for the aging population?Paresh Vyas, Douglas R Higgs
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2022
Shall We Dance: Evolving Partnerships of Targeted Therapies for AMLAlexander E Perl, Paresh Vyas
Current Opinion in Pediatrics|January 17, 2007
Molecular insights into Down syndrome-associated leukemiaParesh Vyas, John D Crispino
Cancer Discovery|December 4, 2019
Oncogenic Drivers and DevelopmentDavid Cruz Hernandez, Paresh Vyas
Cell Stem Cell|August 12, 2009
Molecular targeting of cancer stem cellsRajeev Gupta, Paresh Vyas, Tariq Enver
Cell Stem Cell|March 3, 2011
Clever leukemic stem cells branch outParesh Vyas, Sten Eirik W Jacobsen
Current Opinion in Oncology|September 1, 2010
Assessment of minimal residual disease in acute myeloid leukemiaDavid Grimwade, Paresh Vyas, Sylvie Freeman
Pageof 21

Showing results (11-20 of 201) with videos related to

Sort By:
Pageof 21
Early Human Development|October 27, 2006
Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesisParesh Vyas, Irene Roberts
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AMLGert Ossenkoppele, Paresh Vyas
Clinical Medicine (London, England)|April 28, 2018
From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemiaNiels Asger Jakobsen, Paresh Vyas
Blood|October 9, 2008
Good news for the aging population?Paresh Vyas, Douglas R Higgs
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2022
Shall We Dance: Evolving Partnerships of Targeted Therapies for AMLAlexander E Perl, Paresh Vyas
Current Opinion in Pediatrics|January 17, 2007
Molecular insights into Down syndrome-associated leukemiaParesh Vyas, John D Crispino
Cancer Discovery|December 4, 2019
Oncogenic Drivers and DevelopmentDavid Cruz Hernandez, Paresh Vyas
Cell Stem Cell|August 12, 2009
Molecular targeting of cancer stem cellsRajeev Gupta, Paresh Vyas, Tariq Enver
Cell Stem Cell|March 3, 2011
Clever leukemic stem cells branch outParesh Vyas, Sten Eirik W Jacobsen
Current Opinion in Oncology|September 1, 2010
Assessment of minimal residual disease in acute myeloid leukemiaDavid Grimwade, Paresh Vyas, Sylvie Freeman
Pageof 21